Bisphosphonate-associated osteonecrosis of the jaws: Systematic review;Osteonecrosis de los maxilares asociada a bifosfonatos: Revisión sistemática

Avances en Odontoestomatologia

Volumn 23, Issue 2, 2007, Pages 91-101

  Escobar Lopez E A ^a,c   Lopez Lopez J ^a   Marques Soares, M S ^b   Chimenos Kustner E ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

^c NONE   (Spain)

Author keywords

Bisphosphonates; Jaws; Osteonecrosis; Pamidronate; Zoledronate

Indexed keywords

EID: 77749334345     PISSN: 02131285     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Sung EC, Chan SM, Sakurai K, Chung E. Osteonecrosis of the maxilla as a complication to chemotherapy: a case report. Spec Care Dentist 2002;22:142-6.
2. Hui L, Wiernik PH. Avascular Necrosis of bone after adult acute lymphocytic leukemia treatment with methotrexate, vincristine, L-asparaginase and dexamethasone (MOAD). Am J Hematol 1996;52:184-8.
3. Thorn JJ, Hansen HS, Specht L, Bastholt L. Osteoradionecrosis of the jaws: clinical characteristics and relation to the field of irradiation. J Oral Maxillofac Surg 2000;58:1088-93.
4. Reuther T, Schuster T, Mende U, Kübler A. Osteoradionecrosis of the jaws as a side effect of radiotherapy of head and neck tumour patientsa report of a thirty year retrospective review. Int J Oral Maxillofac Surg 2003;32:289-95.
5. Marx RE. Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-8.
6. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003;61:1104-7.
7. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21: 4253-4.
8. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006;17:897-907.
9. Licata AA. Discovery, Clinical Development, and Therapeutic Uses of Bisphosphonates. Ann Pharmacother 2005;39:668-77.
10. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;86:2961-78.
11. Vitt́ C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 1996;137:2324-33.
12. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10:1478-87.
13. Plotkin LI, Agurre JI, Kousteni S, Manolagas SC, Bellido T. Bisphosphonates and Estrogens Inhibit Osteocyte Apoptosis via Distinct Molecular Mechanisms Downstream of Extracellular Signalregulated Kinase Activation. J Biol Chem 2005;280:7317-25.
14. Wood J, Bonjean K, Ruetz S, Bellahćne A, Devy L, Foidart JM. Castronovo V, Green JR. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302:1055-61.
15. Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer 2001;61:2602-8.
16. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer 1997;57:3890-4.
17. Tassone P, Tagliaferri P, Viscomi C. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 2003;88:1971-8.
18. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM, Clezardin P. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949-54.
19. Expert Panel Recommendations for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaws: June 2004. Professional Education Material. East Hanover, NJ: Novartis; 2004.
20. Migliorati Ca, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis. Journal American Dental Association 2005;136: 1658-68.
21. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527- 34.
22. Lugassy G, Shaham R, Nemets A, Ben-Dor D, Nahlieli O. Severe osteomyelitis of the jaw in long term survivors of multiple myeloma: a new clinical entity. Am J Med 2004;117:440-1.
23. Thakkar SG, Isada C, Englund K, Tomford W, Karam MA, Reed JL, Smith J, Hussein MA. Bisphosphonate therapy associated with an increased incidence of mandibular/maxillary osteomyelitis in multiple myeloma patients. Blood 2004;104:4925.
24. Schuster MW, Dymek JM. Oral cavity avascular bone necrosis a newly recognized complication of intravenous (iv) bisphosphonate therapy in cancer patients. Blood 2004;104:4905.
25. Pires FR, Miranda A, Cardoso ES, Cardoso AS, Fregnani ER, Pereira CM, Correa ME, Almeida JP, Alves Fde A, Lopes MA, de Almeida OP. Oral avascular bone necrosis associated with chemotherapy and bisphosphonate therapy. Oral Dis 2005;11:365-9.
26. Bagán JV, Jiḿnez Y, Murillo J, Hernández S, Poveda R, Sanchís JM, Díaz JM, Scully C. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol 2006;42:327-9.
27. Gibbs SD, O'Grady J, Seymour JF, Prince HM. Bisphosphonate-induced osteonecrosis of the jaw requires early detection and intervention. Med J Aust 2005;183:549-50.
28. Merigo E, Manfredi M, Meleti M, Corradi D, Vescovi P. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report. J Oral Pathol Med 2005;34: 613-7.
29. Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust 2005;182:413-5.
30. Lenz JH, Steiner-Krammer B, Schmidt W, Fietkau R, Mueller PC, Gundlach KK. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates? J Craniomaxillofac Surg 2005;33: 395-403.
31. Ficarra G, Beninati F, Rubino I, Vannucchi A, Longo G, Tonelli P, Pini Prato G. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 2005;32:1123-8.
32. Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. J Am Dent Assoc 2005;136: 1675-81.
33. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate- associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005; 104:83-93.
34. Olson KB, Hellie CM, Pienta KJ. Osteonecrosis f jaw in patient with hormone refractory prostate cancer treated with zoledronic acid. Urology 2005; 66:658.e1-658.e3.
35. Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Aust 2005;182:417-8.
36. Vannucchi AM, Ficarra G, Antonioli E, Bosi A. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br J Haematol 2005;128:738.
37. Katz H. Endodontic implications of bisphosphonate- associated osteonecrosis of the jaws: a report of three cases. J Endod 2005;31:831-4.
38. Sarathy AP, Bourgeois SL Jr, Goodell GG. Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports. J Endod 2005;31:759-63.
39. Schirmer I, Peters H, Reichart PA, Durkop H. Bisphosphonates and osteonecrosis of the jaw. Mund Kiefer Gesichtschir 2005;9:239-45.
40. Guarneri V, Donati S, Nicolini M, Giovannelli S, D'Amico R, Conte PF. Renal Safety and Efficacy of i.v. Bisphosphonates in Patients with Skeletal Metastases Treated for up to 10 Years. Oncologist 2005; 10:842-8.
41. Markiewicz MR, Margarone JE, Campbell JH, Aguirre A. Bisphosphonate- associated osteonecrosis of the jaws: a review of current knowledge. J Am Dent Assoc 2005;136:1669-74.
42. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23:8580-7.
43. Dimitrakopoulos I, Magopoulos C, Karakasis D. Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases. Int J Oral Maxillofac Surg 2006;35:588-93.
44. Mignogna MD, Lo Russo L. Osteonecrosis of the Jaws Associated With Bisphosphonate Therapy. J Clin Oncol 2006;24:1475-7.
45. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T. Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk Factors. Journal of Clinical Oncology 2006;24:945-52.
46. Farrugia MC, Summerlin DJ, Krowiak E,Huntley T, Freeman S, Borrowdale R, Tomich C. Osteonecrosis of the Mandible or Maxilla Associated with the use of New Generation Bisphosphonates. Laryngoscope 2006;116:115-20.
47. Hansen T, Kunkel M, Weber A, Kirkpatrick CA. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis incomparison with infected osteoradionecrosis. J Oral Pathol Med 2006;35:155-60.
48. Pastor-Zuazaga D, Garatea-Crelgo J, Martino- Gorbea R, Etayo-Ṕrez A, Sebastián-López C. Osteonecrosis of the jaws and bisphosphonates. Report of three cases. Med Oral Patol Oral Cir Bucal 2006; 11:E76-9.
49. Zarychanski R, Elphee E, Walton P, Johnston J. Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol 2006;81: 73-5.
50. Carneiro E, Vibhute P, Montazem A, Som PM. Bisphosphonate-Associated Mandibular Osteonecrosis. Am J Neuroradiol 2006;27:1096-7.
51. Soileau KM. Oral post-surgical complications following the administration of bisphosphonates given for osteopenia related to malignancy. J Periodontol 2006; 77:738-43.
52. González-Moles MA, Bagán-Sebastián JV. Alendronate-related oral mucosa ulcerations. J Oral Pathol Med 2000;29:514-8.
53. Demerjian N, Bolla G, Spreux A. Severe oral ulcerations induced by alendronate. Clin Rheumatol. 1999; 18:349-50.
54. Krasagakis K, Krüger-Krasagakis S, Ioannidou D, Tosca A. J Am Acad Dermatology 2004;50: 671-2.
55. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353:99-102.
56. Estilo CS, Van Poznak CH, Williams T, Evtimovska E, Tkach L, Halpern JL, et al. Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: a retrospective study. Proc Am Soc Clin Oncol 2004;22:750.
57. Tarassoff P, Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 2003;61:1238-9.
58. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-61.
59. Mashiba T, Mori S, Burr DB, Komatsubara S, Cao Y, Manabe T, et al. The effects of suppressed bone remodeling by bisphosphonates on micro damage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 2005;23 Suppl:36-42.
60. Polizzotto MN, Cousins V, Schwarer AP. Bisphosphonate- associates of the auditory canal Br J Haematol 2005;132:114-7.
61. Parfett AM: Osteonal and hemiosteonal remodeling, the spatial and temporal framework for signal traffic in adult human bone. J Cellular Biochem 1994; 55:273.
62. Reszka AA, Halasy-Nagy J, Rodan GA. Nitrogenbisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthesis pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 2001;59:193-202.
63. Nair SP, Meghij S, Wilson M, Reddi K, White P, Henderson B. Bacterially induced bone destruction: mechanisms and misconceptions. Infect Immun 1996;64:2371- 80.